Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.

Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT ...

Medically reviewed by Lindsay Cook, PharmD Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved to help manage and offer relief for people dealing with migraine headaches ...

D.R. Horton (NYSE: DHI), the largest U.S. homebuilder by volume, has taken investors on a roller-coaster ride over the last ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

The settlement resolves allegations that Biohaven paid improper remuneration, including speaker honoraria and high-end restaurant meals, to physicians and other healthcare professionals to promote ...

The claims and ensuing settlement revolve around Biohaven’s CGRP receptor antagonist Nurtec ODT, which is cleared to both treat and prevent migraines in adults. The drug, which was the crown ...

Pfizer (NYSE:PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to physicians to induce prescriptions for its migraine drug Nurtec ODT. The U.S ...

Pfizer paid $11.6bn to buy Biohaven, largely on the financial performance of Nurtec ODT. The drug went on to generate global sales of $928m in sales in 2023. Known as Vydura in Europe, Nurtec ODT ...